High expression of NEK2 mediated by p53 contributes to progression and relapse of multiple myeloma
X. Feng,J. Guo,Y. Wu,B. Meng,Y. Zhu,G. An,Z. Liu,J. Xia,Y. Guan,X. Zhao,L. Qiu,J. Zhou,F. Zhan,W. Zhou
DOI: https://doi.org/10.1182/blood-2018-192
IF: 20.3
2019-01-01
Blood
Abstract:High expression of NEK2 mediated by p53 contributes to progression and relapse of multiple myeloma Xiangling Feng 1,2 , Jiaojiao Guo 1 , Bowen Ouyang 2 , Yinghong Zhu 1 ,Gang An 3 , Hao Zhen 1 , Jiliang Xia 1 , Yongjun Guan 1 , Xinying Zhao 2 , Lugui Qiu 3 , Jiaxi Zhou 3 , Fenghuang Zhan 4 ,Wen Zhou 1 1 , Cancer Research Institute,Central South University, Changsha 410078, China. 2 Xiang Ya School of Public Health, Central South University, Changsha, Hunan, China. USA. 3 State Key Laboratory of Experimental Hematology, Institute of Hematology u0026 Blood Diseases Hospital, Chinese Academy of Medical Science u0026 Peking Union Medical College, Tianjin, China. 4 Department of Internal Medicine, Division of Hematology, Oncology, and Blood u0026 Marrow Transplantation, University of Iowa, Iowa City, USA. E-mail: wenzhou@csu.edu.cn. Background: Loss of p53 is an independent prognostic factor in patients with multiple myeloma (MM). Our previous studies found abnormal high expression of NEK2 was closely related to the poor prognosis and drug resistance of myeloma patients. However, it9s unclear how NEK2 was up-regulated in MM. Through bioinformatics analysis, the binding site of p53 protein is found in NEK2 promoter, but the relationship and function of p53 and NEK2 in MM are poorly understood. Materials and Methods: In this study, p53-/- MM cell lines (ARP1 and KMS11) and p53 p53+/+ MM cell lines (MM1S and H929) were used for investigating the role of NEK2 in p53-/- MM cell. FISH was performed on interphase nuclei of MM primary cells to detect p53 and NEK2 copy numbers. Chromatin immunoprecipitation and fluorescence reporter system were applied for examining the binding site of p53 protein in the distal NEK2 promoter. CGH and RNA-seq were performed to validate copy number changes and variations in the expression of several transcripts. Results: The top 10% of MM patients with the highest NEK2 expression and lowest p53 had a significantly inferior OS (P Conclusion: In summary, p53 deletion and NEK2 overexpression induced cancer cell drug resistance, proliferation and chromosomal instability. p53 could bind to the promoter region of NEK2 and cause NEK2 amplification. Down-regulation of NEK2 by shRNA in p53 deletion cells inhibited cell growth in vitro and in vivo. Thus,The significance of this study will provide the pre-clinical application of the NEK2 inhibitor to overcome the drug resistance induced by p53 in MM. Disclosures No relevant conflicts of interest to declare.